How the Brain Changes on Ketamine: A Live Animal Study
Ruth Williams | Apr 11, 2019
The drug promotes and sustains brain cell connectivity in mice, reversing the effects of chronic stress.
Biogen, Eisai End Two Late-Stage Trials for Alzheimer’s Treatment
Biogen, Eisai End Two Late-Stage Trials for Alzheimer’s Treatment
The widely expected move comes months after the companies scrapped trials of another Alzheimer’s drug.
The widely expected move comes months after the companies scrapped trials of another Alzheimer’s drug.
Mopping Up Excess Chemotherapy Drugs
Ruth Williams | Apr 1, 2019
A prototype in-vein device would collect toxic medications before they reach healthy tissues.
Lasker Awards Recognize Work on Histones, Anesthesia, RNA
Shawna Williams | Sep 11, 2018
This year’s winners are C. David Allis, Michael Grunstein, John Glen, and Joan Steitz.
FDA Approves First Marijuana-Derived Drug
Shawna Williams | Jun 25, 2018
As the CBD-based medication enters the market, the agency promises a crackdown on producers of cannabidiol products that make unproven claims.
Researchers Getting Smarter About Pairing Cancer Treatments
Anna Azvolinsky | Apr 1, 2018
Multidrug combinations lead to better results for cancer patients, but efficiently identifying them is proving difficult.
Infographic: Cancer Drug Pairings
Anna Azvolinsky | Mar 31, 2018
Researchers use several different strategies to deliver a one-two punch.
Pfizer to Halt Alzheimer’s and Parkinson’s Drug Research
Jim Daley | Jan 7, 2018
The company’s recent effort to find new treatments for Alzheimer’s ended in disappointment.
Clinical Trial Reporting for Pharma-Sponsored Trials Shows Improvement
Diana Kwon | Dec 4, 2017
The Good Pharma Scorecard finds some big pharmaceutical companies are meeting legal standards for disclosing results—but many studies still go unreported.
RNA Interference Drug Excels in Clinical Trials to Treat Rare Disorder
Katarina Zimmer | Nov 3, 2017
If approved, patisiran will be the first RNAi therapeutic on the market.